We're changing the face of clinical trials using smart, randomized trial design
Our streamlined approach and scalable digital infrastructure transforms the way randomized controlled trials are conducted. We work together with our partners to generate robust evidence for new treatments at a fraction of current industry costs. This helps us to reduce the barriers in the development of and access to better treatments for common diseases.
A truly integrated approach
We are driving change in the design, management and delivery of clinical trials. By having the right partnerships, systems, processes and capabilities in place, we can deliver definitive, streamlined and cost effective clinical trials.
We work closely with our partners from start to finish. Together with them, we design and manage smart, highly efficient trials that combine the fundamental principles of randomization, with advances in health data and technology. We involve the clinical and patient communities that participate in our trials or stand to gain from the results they generate. We work closely with regulators and others to ensure that our trials deliver results that facilitate prompt licensing, market access and purchasing decisions. Together, this ensures our trials provide robust evidence for treatments with huge potential impact on health.
Each trial is tailored to meet the specific scientific, regulatory, clinical, and patient needs. Trials are developed and delivered using a quality-by-design approach that considers the full life-cycle of each trial from planning and recruitment to generation of robust and relevant results for regulatory, payer and clinical decision-makers. The operations are underpinned by our flexible, secure, standards-based IT platform that can be tailored for each individual protocol and make appropriate use of routine health data and patient-centered technology. We use statistical and risk-based approaches to monitoring and quality management to improve results and significantly reduce trial costs.
Through this integrated approach, we aim to vastly improve the pipeline of treatments for common diseases.
Quality and trust
Quality and trust are vital to our work. We are committed to taking a quality-led approach, including implementing a Quality Management System that is on track to receive ISO9001:2015 accreditation in autumn 2023. We take information security seriously and use data safely, responsibly and in accordance with all relevant ethical and legal requirements.
Our Information Security is of the highest standard, receiving ISO27001:2013, Cyber Essentials and Cyber Essentials Plus accreditations. We have passed the standards of the NHS Data Security and Protection Toolkit, which provides assurance that we are practicing good data security and handling personal information correctly.
Patient and public engagement
Patients and the public provide valuable insights into the design and delivery of clinical trials, helping to ensure that the results and their application to medical practice meets their needs. We will be forming a Patient and Public Involvement and Engagement Panel in the coming months to inform the design of our studies.
Collaborate with us
We are interested in opportunities to partner with pharmaceutical companies, biotech, academic research teams, healthcare providers, charities and investment organisations that share our mission to accelerate the adoption of novel treatments through robust randomized controlled trials.
Latest news & stories
“A New National Purpose”: Protas named in report on innovation
Protas was this week named in a new report exploring how the UK should harness innovation in science and technology…
Protas signs strategic partnership with Moderna
Protas is delighted to announce a new strategic partnership with Moderna, the leading biotechnology company pioneering messenger RNA (mRNA). Moderna’s…